Jaguar Health Poised for Breakthrough with Crofelemer Trials

This is not a postmortem. It is more like a prognosis.
My view is that Jaguar still has a living clinical story, but a gravely impaired equity story. Those are not the same thing. The company is still advancing crofelemer in MVID / intestinal-failure-related programs, is talking about a possible Breakthrough Therapy designation plan in the coming months, and says it is in discussions for non-dilutive partner funding. So the underlying orphan-disease narrative is not dead.
What I think the future holds for Jaguar is this:
Most likely path: more promotional and developmental updates, but no durable stock recovery unless one of three things happens:

1. they secure meaningful non-dilutive funding or a partner,
2. they produce unusually compelling regulatory/clinical traction in MVID, or
3. they solve the listing/capital-structure problem enough that the market stops treating the stock like a near-corpse. Jaguar’s recent financials are still ugly: about $11.5 million of 2025 revenue, a $53.6 million net loss, and Nasdaq delisting proceedings that were still active enough to require a hearing/stay process this month.

So for the company, I think the future is:
ongoing rare-disease pursuit, constant search for funding, repeated attempts to frame crofelemer as a valuable orphan asset, and occasional headline bursts around FDA interactions, conferences, partnerships, or “AI-enabled efficiency.”
For the stock, I think the future is probably binary and unstable:
it can absolutely have violent spikes on hopeful news, but unless the company lands something concrete, those spikes are likely to remain tradable bursts rather than a true rerating. The market cap is only around $5 million, and the stock has fallen from around $2.04 in July 2025 to roughly $0.38 in April 2026, which tells you the market has been steadily discounting the story despite all the updates.
So I would phrase it this way:
Is Jaguar dead? No.
Is Jaguar healthy? Also no.
Could it spike? Definitely.
Would I trust it to grind upward into a stable breakout without a major external validation event? No.
If I were reducing this to a practical ScanScor-style judgment, I would say the future most likely holds event-driven pops, financing stress, and continued survival behavior, unless a partner or FDA-pathway development changes the entire tone of the situation. That means the prediction window can still produce a surprise move, but at this point the burden of proof is on Jaguar, not on skepticism.